LGVN vs LLY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
LGVN exhibits severe financial distress, highlighted by a Piotroski F-Score of 1/9, indicating critical weakness in nearly all fundamental health categories. The company suffers from extreme operating losses (-1479.18% margin) and negative revenue growth (-39.50% YoY), suggesting a failing business model or a high-risk clinical stage. While the current ratio of 1.33 provides a temporary liquidity cushion and analyst targets are aggressively optimistic, the deterministic data points to a high probability of further capital erosion.
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
LGVN vs LLY: Head-to-Head Comparison
This page compares Longeveron Inc. (LGVN) and Eli Lilly and Company (LLY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.